Invesco Biotechnology & Genome ETF (PBE) price, chart and fund profile
Price chart
Fund profile
PBE tracks a tiered equal-weighted index of companies principally engaged in biotechnology and genetic engineering.
- Issuer
- Invesco Capital Management LLC
- Industry
- Healthcare
- Inception
- Jun 23, 2005
- Assets under management
- $399.1M
- Expense ratio
- 0.58%
- Net asset value
- $96.39
- NAV as of
- Aug 28, 2026
- Leverage
- 1×
- Fund page
- www.invesco.com↗
Frequently asked questions
What is Invesco Biotechnology & Genome ETF (PBE)?
PBE tracks a tiered equal-weighted index of companies principally engaged in biotechnology and genetic engineering.
What is PBE's expense ratio?
Invesco Biotechnology & Genome ETF charges an annual expense ratio of 0.58%. The fund is issued by Invesco Capital Management LLC.
How large is PBE?
Invesco Biotechnology & Genome ETF manages $399.1M in assets and has traded since Jun 23, 2005.
How do I buy shares of Invesco Biotechnology & Genome ETF (PBE)?
PBE trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web dashboard at portal.lighthorse.io, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.